CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 18 enrolled / 18 target
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03085719
NCT03085719Phase 2ActiveUpdate Overdue (0.2/mo)Completion was 43mo ago
CompareCT.gov

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Dana-Farber Cancer Institute·interventional·Posted Mar 21, 2017·Updated Jun 15, 2026

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab and Radiation for Head and Neck Cancer. Active but no longer recruiting, targeting 18 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body. The immunotherapy involved in this study is: MK-3475 (pembrolizumab or KEYTRUDA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2Active
201720182019202020212022202320242025202620272028
First PostedMar 21, 2017
Enrollment StartJun 30, 2017
Primary CompletionNov 1, 2022
Study CompletionOct 31, 2027
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.3 years ago

Arms & Interventions

High Dose Radiation + Pembrolizumabexperimental

* High dose radiation will be given in 3 fractions * Pembrolizumab administered intravenously on day one of each cycle.

Drug: PembrolizumabRadiation: Radiation
High Dose + Low Dose Radiation + Pembrolizumabexperimental

* High Dose radiation will be given in 3 fractions * Low Dose Radiation will be given in 2 fractions * Pembrolizumab administered intravenously on day one of each cycle.

Drug: PembrolizumabRadiation: Radiation

Interventions

Pembrolizumabdrug

Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells

Radiationradiation

Radiation is used to shrink the cancer